Victory Capital Management Inc. bought a new position in shares of Astrana Health, Inc. (NASDAQ:ASTH - Free Report) in the third quarter, according to the company in its most recent filing with the SEC. The fund bought 44,806 shares of the company's stock, valued at approximately $2,596,000. Victory Capital Management Inc. owned 0.09% of Astrana Health as of its most recent filing with the SEC.
A number of other institutional investors and hedge funds have also recently bought and sold shares of ASTH. Amalgamated Bank acquired a new position in Astrana Health during the third quarter valued at approximately $713,000. Principal Financial Group Inc. acquired a new position in shares of Astrana Health during the 3rd quarter valued at $13,383,000. Diamond Hill Capital Management Inc. acquired a new position in shares of Astrana Health during the 3rd quarter valued at $8,245,000. Summit Global Investments purchased a new stake in Astrana Health during the 3rd quarter worth $753,000. Finally, Louisiana State Employees Retirement System acquired a new stake in Astrana Health in the 3rd quarter valued at $1,165,000. Institutional investors and hedge funds own 52.77% of the company's stock.
Astrana Health Stock Performance
Shares of ASTH stock remained flat at $42.11 during mid-day trading on Friday. 280,101 shares of the stock were exchanged, compared to its average volume of 320,497. The company has a quick ratio of 1.91, a current ratio of 1.91 and a debt-to-equity ratio of 0.60. The company has a fifty day moving average price of $54.17 and a 200 day moving average price of $47.94. The company has a market capitalization of $2.37 billion, a P/E ratio of 32.39, a P/E/G ratio of 1.95 and a beta of 1.24. Astrana Health, Inc. has a twelve month low of $32.32 and a twelve month high of $63.20.
Astrana Health (NASDAQ:ASTH - Get Free Report) last announced its quarterly earnings data on Thursday, November 7th. The company reported $0.33 earnings per share for the quarter, hitting the consensus estimate of $0.33. Astrana Health had a net margin of 3.63% and a return on equity of 9.37%. The company had revenue of $478.71 million during the quarter, compared to analyst estimates of $462.01 million. During the same period last year, the business earned $0.47 EPS. On average, analysts forecast that Astrana Health, Inc. will post 1.17 EPS for the current year.
Wall Street Analyst Weigh In
ASTH has been the topic of a number of recent research reports. KeyCorp started coverage on Astrana Health in a research note on Friday, October 11th. They set a "sector weight" rating on the stock. Robert W. Baird boosted their price target on Astrana Health from $67.00 to $86.00 and gave the stock an "outperform" rating in a research report on Wednesday, November 13th. TD Cowen assumed coverage on shares of Astrana Health in a research report on Monday, October 14th. They issued a "buy" rating and a $66.00 price objective for the company. BTIG Research lifted their price objective on shares of Astrana Health from $60.00 to $70.00 and gave the company a "buy" rating in a research note on Thursday, October 3rd. Finally, Stifel Nicolaus upped their target price on shares of Astrana Health from $48.00 to $60.00 and gave the company a "buy" rating in a research note on Thursday, August 1st. One analyst has rated the stock with a hold rating, six have given a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, Astrana Health has a consensus rating of "Buy" and a consensus price target of $65.17.
Read Our Latest Stock Analysis on ASTH
Astrana Health Profile
(
Free Report)
Astrana Health, Inc, Inc, a physician-centric technology-powered healthcare management company, provides medical care services in the United States. It operates through three segments: Care Partners, Care Delivery, and Care Enablement. The company is leveraging its proprietary population health management and healthcare delivery platform, operates an integrated, value-based healthcare model which empowers the providers in its network to deliver care to its patients.
Further Reading
Before you consider Astrana Health, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Astrana Health wasn't on the list.
While Astrana Health currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
